Menu Search
Equities

Gyre Therapeutics Inc

L9S:FRA

Gyre Therapeutics Inc

Actions
  • Price (EUR)14.00
  • Today's Change-0.300 / -2.10%
  • Shares traded-1.00
  • 1 Year change+377.65%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 07:01 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Gyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in the research, development, manufacturing and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). The Company is also advancing a diverse pipeline in China through a controlling interest in Beijing Continent, including pirfenidone, F573, F528, and F230. Pirfenidone is used for idiopathic pulmonary fibrosis and is undergoing Phase III trials in dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, along with a Phase I trial in diabetic kidney disease. F573 is being investigated for acute-on-chronic liver failure, while F528 and F230 are being evaluated for chronic obstructive pulmonary disease and pulmonary arterial hypertension, respectively.

  • Revenue in USD (TTM)0.00
  • Net income in USD-44.24m
  • Incorporated1997
  • Employees7.00
  • Location
    Gyre Therapeutics Inc12770 High Bluff Drive, Suite 150SAN DIEGO 92130United StatesUSA
  • Phone+1 (619) 949-3681
  • Fax+1 (302) 636-5454
  • Websitehttps://www.gyretx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.